Safety and Acceptability of Deferiprone Delayed Release Tablets in Patients With Systemic Iron Overload

ApoPharma30 enrolled

Overview

Safety, tolerability, and acceptability of twice-daily dosing with deferiprone delayed-release (DR) tablets in patients with systemic iron overload.

This study is looking at the safety, tolerability, and acceptability of twice-daily dosing with deferiprone delayed-release (DR) tablets in patients with systemic iron overload who are currently taking deferiprone immediate-release tablets (Ferriprox) three times a day. Ferriprox doses range from 75 milligrams per kilogram of body weight (mg/kg) per day to 100 mg/kg per day. Half the patients in the study will be on a dosage that is closer to the low end of the range, and half will be on a dosage that is closer to the high end. Both groups will be switched for one month to deferiprone DR tablets at approximately the same total daily dosage that they have been taking for Ferriprox.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Iron Overload Due to Repeated Red Blood Cell Transfusions

Interventions

Deferiprone DR tablets 1000 mg (Low dosage)DRUG

Deferiprone DR tablets 1000 mg

Deferiprone DR tablets 1000 mg (High dosage)DRUG

Deferiprone DR tablets 1000 mg

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. Male or female aged ≥ 18 years. 2. Diagnosis of thalassemia syndrome, sickle cell disease, or other disorder requiring a regular regimen of red blood cell transfusions. 3. On a stable regimen (≥3 months) of Ferriprox tablets for the treatment of systemic iron overload. 4. Absolute neutrophil count ≥1.5 x 10\^9/L at screening. 5. A record of at least 12 measured alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels. Exclusion Criteria: 1. Receipt of any iron chelator other than Ferriprox (i.e., combination therapy) in the last 3 months, or planning to receive it at any time during the period of the study. 2. ALT and/or AST value \> 5 times the upper limit of normal (ULN) at screening 3. Active case of hepatitis B or C at screening.

Locations (5)

Ann & Robert H. Lurie Children's Hospital of Chicago

Chicago, Illinois, United States

New York Presbyterian Hospital/Weill Cornell Medical Center

New York, New York, United States

St.Paul's Hospital

Vancouver, British Columbia, Canada

National and Kapodistrian University of Athens, Aghia Sophia Children's Hospital

Goudi, Athens, Greece

Outcomes

Primary Outcomes

The Percentage of Patients in Each Treatment Group Who Experience Post-dose Increases in Liver Enzyme Levels That Are Considered a Safety Concern.

Levels of the liver enzymes alanine aminotransferase (ALT) and aspartate aminotransferase (AST) will be assessed throughout the study to determine if any patients have post-dose increases that are considered to be a safety concern. The criteria for being considered a safety concern are meeting one of the following: * For a patient whose level was within the normal range at baseline, the criterion is reaching a value of 5 times the upper limit of normal (ULN) * For a patient whose level was above the ULN at baseline, the criterion is reaching either 5 times the baseline value or 10 x ULN

Time frame: Day 28

Secondary Outcomes

The Percentage of Patients in Each Treatment Group Who Report Post-dose Occurrences of Gastrointestinal (GI) Distress.

Patients will be asked to report any events of GI distress during the study, such as nausea, vomiting, diarrhea, abdominal pain, and dyspepsia.

Time frame: Day 28

The Percentage of Patients in Each Group Who Indicate That They Prefer the Deferiprone DR Formulation Over the Immediate-release Formulation.

At the end of the study, patients will complete a questionnaire to indicate which formulation they prefer.

Time frame: Day 28

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.